

# THE GLOBAL MARKET FOR PAIN MANAGEMENT DRUGS AND DEVICES



**HLC026D**  
**January 2013**

Melissa Elder  
***Project Analyst***

ISBN: 0-89336-712-5

**bcc** | Research  
Market Forecasting

**BCC Research**  
**49 Walnut Park, Building 2**  
**Wellesley, MA 02481**  
**866-285-7215, 781-489-7301**  
**www.bccresearch.com**  
**Custom Reports: carol.laverty@bccresearch.com**

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	1
STUDY GOALS AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	1
SCOPE AND FORMAT	1
METHODOLOGY	2
ANALYST CREDENTIALS	2
RELATED BCC STUDIES	2
BCC ON-LINE SERVICES	2
DISCLAIMER	3
CHAPTER 2 SUMMARY	5
OVERVIEW	5
GENERAL PAIN TERMINOLOGY	5
MAJOR MARKETS SUMMARY	6
<i>SUMMARY TABLE GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET, 2012 AND 2017 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET, 2012 AND 2017 (\$ MILLIONS)</i>	7
MARKET TRENDS	7
UNDER-TREATMENT ISSUES	8
PROFESSIONAL PAIN TREATMENT ISSUES	8
ACCESS TO CARE	8
GLOBAL HEALTHCARE SYSTEMS	8
FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES	8
DRUG DELIVERY SYSTEMS	9
COMPETITORS	9
CHAPTER 3 INDUSTRY OVERVIEW	11
HISTORY OF PAIN AND PAIN TREATMENT	11
THE PERCEPTION OF PAIN	12
Types of Pain	12
Acute Pain	12
Chronic Pain	13
ASSESSMENT OF PAIN	13
Subjective	13
Objective	13
<i>TABLE 1 OBJECTIVE SIGNS OF PAIN</i>	14
HOW PAIN IS DIAGNOSED	14
THERMOGRAPHY	15
HOW PAIN IS TREATED	15
<i>FIGURE 1 PAIN-MANAGEMENT TECHNIQUES</i>	15
DEMOGRAPHICS AND AGING POPULATIONS	20
Global Demographics	20
<i>TABLE 2 ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)</i>	21

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 2 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)</i>	21
<i>TABLE 3 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)</i>	22
<i>FIGURE 3 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015 (MILLIONS)</i>	22
Global Life Expectancy	23
<i>TABLE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)</i>	23
<i>FIGURE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)</i>	24
GLOBAL PAIN MANAGEMENT	24
<i>FIGURE 5 GLOBAL CANCER DEATHS BY TYPE, 2008 (THOUSANDS)</i>	25
INCIDENCE OF PAIN	26
PREVALENCE OF PAIN	26
Severe Headache or Migraine, Low Back, and Neck Pain	26
<i>TABLE 5 SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009 (%)</i>	26
<i>FIGURE 6 SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009 (%)</i>	27
Orthopedic Pain	28
Osteoarthritis	28
Rheumatoid Arthritis	28
Ankylosing Spondylitis	28
Fibromyalgia	29
Gout	29
Scleroderma	29
Lupus	29
Bursitis and Tendonitis	29
Osteoporosis	30
Low Bone Mass	30
<i>TABLE 6 ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE, 2008-2010</i>	30
<i>FIGURE 7 ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE 2008-2010</i>	31
Cancer Pain	31
<i>FIGURE 8 CAUSES OF CANCER PAIN</i>	32
Pain Management in Cancer	33
<i>TABLE 7 CANCER PAIN MEDICATION</i>	33
Description of Some of Key Medications for Cancer Pain Control	34
Morphine	34
Fentanyl	34
Hydromorphone	34
Methadone	34
Buprenorphine	35
Oxycodone	35
Tapentadol	35
HIV/AIDS Related Pain	35
<i>TABLE 8 ESTIMATED HIV REPORTED CASES BY REGION, 2011</i>	36
<i>FIGURE 9 ADULT PREVALENCE RATE, 2011 (%)</i>	36

<b>TOPIC</b>	<b>PAGE NO.</b>
Burn Pain	36
Burn Classifications	37
<i>TABLE 9 BURN CLASSIFICATIONS</i>	37
Stages of Burn Healing	38
Challenges Associated with Burn Pain	39
Burn Pain Management	39
<i>FIGURE 10 BURN PAIN MANAGEMENT APPROACH</i>	40
Dental Pain	40
Treatment for Dental Pain	41
Obstetrics Pain	41
<i>TABLE 10 BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES</i>	42
<i>FIGURE 11 BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES</i>	42
Surgical pain	42
U.S. Surgical Procedures	43
<i>TABLE 11 U.S. SURGICAL PROCEDURES</i>	44
Global Surgical Procedures	44
<i>TABLE 12 SELECT SURGICAL PROCEDURES FOR GERMANY, UNITED KINGDOM, AND FRANCE</i>	45
GENDER AND PAIN	45
<i>TABLE 13 PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION* (THOUSANDS)</i>	46
<i>FIGURE 12 PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION* (THOUSANDS)</i>	47
OTHER INFLUENCES DETERMINING HOW PAIN IS FELT AMONG INDIVIDUALS	47
Objective Pain Measurement	48
PEDIATRIC PAIN	48
CHAPTER 4 INDUSTRY TRENDS	51
OVERVIEW	51
UNDERTREATMENT ISSUES	51
TREATMENT OF PAIN AND ISSUES FACING THE PROFESSIONAL SEGMENT	53
<i>TABLE 14 AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECT REGION/COUNTRY</i>	55
PRESCRIPTION DRUG MONITORING PROGRAMS	56
<i>TABLE 15 TOTAL NUMBER OF ABUSE TREATMENT FACILITIES AND CLIENTS, 2000-2010</i>	56
<i>FIGURE 13 TOTAL NUMBER OF ABUSE TREATMENT FACILITIES, 2000-2010</i>	56
<i>FIGURE 14 TOTAL NUMBER OF ABUSE TREATMENT CLIENTS, 2000-2010</i>	57
<i>TABLE 16 BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS</i>	58
<i>TABLE 17 STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS</i>	58
<i>TABLE 18 STATE CONTROLLED SUBSTANCES SCHEDULING AUTHORITIES AND OTHER CONTACT INFORMATION</i>	60
<i>TABLE 19 NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT, BY REQUIRING STATE</i>	73
ACCESS TO CARE	73
PHYSICIAN TO PATIENT RATIOS	74
<i>TABLE 20 PHYSICIANS PER 1,000 POPULATION BY YEAR AND COUNTRY (THOUSANDS)</i>	74
<i>FIGURE 15 PHYSICIANS PER 1,000 POPULATION BY COUNTRY, 2010*</i>	75
<i>TABLE 21 NUMBER OF PHYSICIAN PER 100,000 RESIDENT POPULATION, UNITED STATES, 2009</i>	76

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 16 NUMBER OF PHYSICIANS PER 100,000 RESIDENT POPULATION, UNITED STATES 2009</i>	76
ACCESS TO PALLIATIVE CARE	77
AVAILABILITY OF MEDICATIONS	78
<i>TABLE 22 AVAILABILITY OF INJECTABLE MORPHINE BY COUNTRY</i>	78
<i>TABLE 23 AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS BY COUNTRY</i>	79
GOVERNMENT RESTRICTIONS AND SUPPORT	80
Drug Supply	80
Single Convention on Narcotic Drugs	81
Government Subsidies	81
PUBLIC HEALTHCARE SYSTEMS AROUND THE WORLD	81
<i>TABLE 24 WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50 (2000)</i>	82
RISING HEALTHCARE COSTS	83
<i>TABLE 25 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980 TO 2010</i>	83
AVERAGE LENGTH OF STAY	83
<i>TABLE 26 HOSPITAL USAGE STATISTICS, AVERAGE 2000-2010 (DAYS)</i>	84
<i>FIGURE 17 HOSPITAL USAGE STATISTICS (DAYS)</i>	84
MANAGED CARE PAIN MANAGEMENT ISSUES	85
FDA APPROVAL REQUIREMENTS FOR PAIN THERAPIES	85
NEW RULES AND LEGISLATION	86
Risk Evaluation and Mitigation Strategy (REMS)	86
<i>TABLE 27 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, BRAND NAME PRODUCTS</i>	86
<i>TABLE 28 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, GENERIC NAME PRODUCTS</i>	87
<i>TABLE 29 LIST OF TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTS REQUIRED TO HAVE TIRF REMS ACCESS PROGRAM</i>	88
Acetaminophen and FDA Changes	88
<i>TABLE 30 LIST OF MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION PRODUCTS</i>	89
DRUG DELIVERY SYSTEMS	90
ORAL AND EXTENDED RELEASE	90
TOPICAL AND TRANSDERMAL	90
INTRAVENOUS	91
INTRANASAL	91
PATIENT-CONTROLLED ANALGESIA	91
IONTOPHORESIS	91
<i>TABLE 31 ADVANTAGES OF IONTOPHORETIC DRUG DELIVERY</i>	92
ELECTROMECHANICAL TRANSPORT	92
CHAPTER 5 TREATING PAIN	94
PHARMACEUTICAL PAIN MANAGEMENT	94
PRESCRIPTION PAIN MANAGEMENT PRODUCTS	94
<i>TABLE 32 RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-OCTOBER 2012</i>	94
Analgesic Drugs	96
Non-Narcotic	97
Narcotic	97
Full and Partial Agonists	99

<b>TOPIC</b>	<b>PAGE NO.</b>
Agonist-Antagonists	100
Nonsteroid Anti-inflammatory Drugs	101
Anti-migraine Drugs	102
Antidepressant, Anticonvulsants, and Other Pain Relieving Drugs	103
<b>ANESTHETICS</b>	103
General	103
<i>TABLE 33 MOST COMMONLY USED GENERAL ANESTHETIC AGENTS</i>	104
Local/Regional	105
Topical	105
<b>OVER-THE-COUNTER PAIN MANAGEMENT PRODUCTS</b>	105
<b>ANALGESIC DRUGS</b>	105
<i>TABLE 34 ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTS</i>	106
<b>NONSTEROID ANTI-INFLAMMATORY DRUGS</b>	106
Aspirin Products and Aspirin Combination Products	107
<i>TABLE 35 ASPIRIN AND ASPIRIN COMBINATION PRODUCTS</i>	107
Ibuprofen and Ibuprofen Combination Products	107
<i>TABLE 36 IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTS</i>	108
Ketoprofen Products	108
<i>TABLE 37 KETOPROFEN PRODUCTS</i>	108
Naproxen Compounds	108
<i>TABLE 38 OTC NONSTEROID ANTI-INFLAMMATORIES</i>	109
<b>ANTI-MIGRAINE DRUGS</b>	109
<i>TABLE 39 ANTI-MIGRAINE PRODUCTS</i>	109
<b>TOPICAL ANESTHETIC DRUGS</b>	109
<i>TABLE 40 TOPICAL ANESTHETIC PRODUCTS</i>	110
<b>PAIN MANAGEMENT DEVICES</b>	110
<b>TRANSCUTANEOUS ELECTRICAL NERVE STIMULATORS</b>	111
<b>PAIN TEM</b>	112
<b>SPINAL CORD STIMULATORS</b>	112
<b>NEUROMUSCULAR STIMULATORS</b>	113
<b>OTHER PAIN MANAGEMENT DEVICES</b>	114
Electromagnetic Therapy	115
<b>PAIN MANAGEMENT PROCEDURES: STEROIDS, ENDOSCOPY, FLUOROSCOPY</b>	116
<b>ALTERNATIVE METHODS OF PAIN MANAGEMENT</b>	116
<b>PSYCHOLOGICAL THERAPIES</b>	118
Biofeedback	118
Hypnosis	118
Behavior Modification/Operant Conditioning	119
Relaxation and Stress Management Training	119
Imagery	120
Autogenic Training	120
Psychosocial Interventions	120
Distraction and Reframing	120
<b>PHYSICAL THERAPIES</b>	121
Ice	121
Warm Bath	121
Massage	121

<b>TOPIC</b>	<b>PAGE NO.</b>
Joint Mobilization	122
Manipulation	122
Traction	122
Acupuncture/Acupressure	122
Laser Therapy	123
Surgery	124
Radiation Therapy	124
Radio-Frequency Neuroablation, Epiduroscopy	124
<i>TABLE 41 UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY, 2002-2012 (THOUSANDS OF PEOPLE)</i>	125
<i>FIGURE 18 UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY, 2002-2012 (THOUSANDS OF PEOPLE)</i>	125
PAIN MANAGEMENT SERVICES AND ORGANIZATIONS	126
HOME CARE	126
HOSPICE	127
<i>FIGURE 19 TOTAL HOSPICE PATIENTS SERVED BY YEAR, 2006-2010 (TOTAL PATIENTS SERVED, ESTIMATE)</i>	128
<i>TABLE 42 HOSPICE STATISTICS, PATIENTS BY CHARACTERISTICS, 2009 AND 2010 (% OF TOTAL)</i>	129
<i>FIGURE 20 TOTAL HOSPICE PATIENTS BY GENDER, 2009 AND 2010 (% OF TOTAL)</i>	129
<i>FIGURE 21 TOTAL HOSPICE PATIENTS BY AGE, 2009 AND 2010 (% OF TOTAL)</i>	130
<i>TABLE 43 HOSPICE STATISTICS, PATIENTS BY PRIMARY DIAGNOSIS (% OF TOTAL)</i>	130
<i>FIGURE 22 TOTAL HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009 AND 2010 (% OF TOTAL)</i>	131
NATIONAL HOSPICE AND PALLIATIVE CARE ORGANIZATION	132
<i>TABLE 44 NHPCO COMMITTEES AND TASK FORCES</i>	132
HOSPITALS	133
<i>TABLE 45 ESTIMATED NUMBER OF REGISTERED HOSPITALS BY SELECTED COUNTRY, 2010 ESTIMATES</i>	133
<i>TABLE 46 TOTAL NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2010</i>	134
Hospital Departments	134
Emergency Rooms (ER)	134
Critical-Care Units (CCU)	134
PAIN CLINICS	135
SKILLED NURSING FACILITIES	136
CHAPTER 6 PRESCRIPTION PAIN MANAGEMENT MARKET SIZE AND ANALYSIS	138
TOTAL MARKET	138
PRESCRIPTION PAIN MARKETS BY PRODUCT TYPE	138
<i>TABLE 47 GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET AT MANUFACTURERS' SALES LEVELS, THROUGH 2017 (\$ MILLIONS)</i>	139
<i>FIGURE 23 GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET AT MANUFACTURERS' SALES LEVELS, 2008-2017 (\$ MILLIONS)</i>	139
NARCOTIC ANALGESICS	139
NON-NARCOTIC ANALGESICS	140
ANTIMIGRAINE AGENTS	140
ANESTHETICS	140

<b>TOPIC</b>	<b>PAGE NO.</b>
OTHER DRUG CLASSES	141
MARKET PARTICIPANTS	141
NARCOTIC/NON-NARCOTIC MARKET SHARE	141
<i>TABLE 48 PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKET SHARE BY REVENUE, 2012 (\$ MILLIONS)</i>	142
<i>FIGURE 24 PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKET SHARE BY REVENUE, 2012 (\$ MILLIONS)</i>	142
MIGRAINE TREATMENT MARKET SHARE	142
<i>TABLE 49 PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BY REVENUE, 2012 (\$ MILLIONS/%)</i>	143
<i>FIGURE 25 PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BY REVENUE, 2012 (%)</i>	144
ANESTHETIC MARKET SHARE	144
<i>TABLE 50 PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE, 2012 (\$ MILLIONS)</i>	145
<i>FIGURE 26 PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE, 2012 (%)</i>	145
FUTURE MARKET ANALYSIS	145
CHAPTER 7 PAIN MANAGEMENT DEVICE MARKET SIZE AND ANALYSIS	147
TOTAL PAIN MANAGEMENT DEVICE MARKET	147
PAIN MARKETS BY PRODUCT TYPE	147
<i>TABLE 51 GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, THROUGH 2017 (\$ MILLIONS)</i>	148
<i>FIGURE 27 GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, 2008-2017 (\$ MILLIONS)</i>	148
SPINAL CORD STIMULATORS	148
NEUROSTIMULATOR/TENS UNITS	149
OTHER PAIN TREATMENT DEVICES	149
MARKET PARTICIPANTS	149
NEUROMUSCULAR STIMULATOR/TENS MARKET SHARE	149
<i>TABLE 52 GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY DEVICES—MANUFACTURER MARKET SHARE, 2012 (\$ MILLIONS)</i>	150
<i>FIGURE 28 GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY DEVICES—MANUFACTURER MARKET SHARE, 2012 (%)</i>	150
SPINAL CORD STIMULATOR MARKET SHARE	150
<i>TABLE 53 GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012 (\$ MILLIONS)</i>	151
<i>FIGURE 29 GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012 (%)</i>	151
FUTURE MARKET ANALYSIS	151
CHAPTER 8 TOTAL MARKET SUMMARY	153
TOTAL PAIN MANAGEMENT MARKET	153
<i>TABLE 54 PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE, THROUGH 2017 (\$ MILLIONS)</i>	153
<i>FIGURE 30 PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE, 2008-2017 (\$ MILLIONS)</i>	153
MARKET PERCENTAGE BY PRODUCT TYPE	154
<i>TABLE 55 PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BY SEGMENT, 2012 (%/\$ MILLIONS)</i>	154



<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 31 PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BY SEGMENT, 2012 (%)</i>	154
MARKETS BY WORLD REGION	155
<i>TABLE 56 DISTRIBUTION OF GLOBAL PAIN MANAGEMENT REVENUES BY REGION, 2012 (%/\$ MILLIONS)</i>	156
<i>FIGURE 32 PERCENTAGE DISTRIBUTION OF GLOBAL PAIN MANAGEMENT SHARES BY REGION, 2012 (%)</i>	156
CHAPTER 9 INDUSTRY DEVELOPMENTS	158
TIMELINE OF RECENT EVENTS AND DEVELOPMENTS	158
THE PIPELINE	159
<i>TABLE 57 SELECTED PAIN-MANAGEMENT DRUG PIPELINES</i>	159
NEW DEVELOPMENTS IN BREAKTHROUGH CANCER PAIN	162
NEW DEVELOPMENTS IN TREATING NEUROPATHIC PAIN	162
DEVELOPMENTS IN OPIOID-INDUCED CONSTIPATION AND REDUCED COMPLIANCE	163
FUTURE OF PAIN RESEARCH	164
PATIENT OUTCOMES RESEARCH	166
SELECTED PAIN-RELATED ACQUISITIONS AND ALLIANCES	166
JANUARY-OCTOBER 2012	166
2000-2011	167
DRUG PATENTS FOR SELECTED THERAPIES	167
<i>TABLE 58 U.S. PATENT EXPIRATION DATES FOR SELECT PAIN DRUGS</i>	167
IMPACT OF GENERIC PARTICIPATION	168
<i>TABLE 59 FIRST TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS, JANUARY 2004-OCTOBER 2012</i>	169
CHAPTER 10 COMPANY PROFILES	174
PHARMACEUTICAL AND DEVICE PAIN MANAGEMENT MANUFACTURERS	174
ABBOTT LABORATORIES	174
ASTRAZENECA	174
BAXTER INTERNATIONAL INC.	175
DJO GLOBAL, INC.	175
ELI LILLY & CO.	175
ENDO PHARMACEUTICALS, INC.	176
GLAXOSMITHKLINE	176
JOHNSON & JOHNSON	177
MEDTRONIC, INC.	178
MERCK & CO. INC.	178
NOVARTIS INTERNATIONAL AG	179
PFIZER	179
PURDUE PHARMACEUTICALS LP	180
ST. JUDE MEDICAL, INC.	180
CHAPTER 11 APPENDIX I: SELECTED PAIN MANAGEMENT CLINICS-UNITED STATES-BY STATE	183
ALABAMA PAIN CLINICS	183
CALIFORNIA PAIN CLINICS	184
COLORADO PAIN CLINICS	192

<b>TOPIC</b>	<b>PAGE NO.</b>
DELAWARE PAIN CLINICS	193
FLORIDA PAIN CLINICS	193
HAWAII PAIN CLINICS	199
IOWA PAIN CLINICS	199
MAINE PAIN CLINICS	200
NEVADA PAIN CLINICS	200
OREGON PAIN CLINICS	201
PENNSYLVANIA PAIN CLINICS	202
RHODE ISLAND PAIN CLINICS	205
SOUTH DAKOTA PAIN CLINICS	205
TEXAS PAIN CLINICS	206
WASHINGTON PAIN CLINICS	208
CHAPTER 12 APPENDIX II: GLOBAL SELECTED PAIN MANAGEMENT CLINICS, BY COUNTRY	212
ARGENTINA PAIN CLINICS	212
AUSTRALIA PAIN CLINICS	213
BRAZIL PAIN CLINICS	214
GERMANY PAIN CLINICS	215
INDIA PAIN CLINICS	215
ITALY PAIN CLINICS	218
SINGAPORE PAIN CLINICS	218
UNITED KINGDOM PAIN CLINICS	219
CHAPTER 13 APPENDIX III: U.S. PAIN SOCIETIES AND ASSOCIATIONS	222
CHAPTER 14 APPENDIX IV: INTERNATIONAL ASSOCIATIONS AND ORGANIZATIONS	224
CHAPTER 15 APPENDIX V: COMPANY NAMES AND ADDRESSES	226
PAIN MANAGEMENT PHARMACEUTICAL MANUFACTURERS	226

## LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET, 2012 AND 2017 (\$ MILLIONS)	7
TABLE 1 OBJECTIVE SIGNS OF PAIN	14
TABLE 2 ESTIMATED GLOBAL POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)	21
TABLE 3 GLOBAL POPULATION BY SELECTED COUNTRY, THROUGH 2015 (MILLIONS)	22
TABLE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)	23
TABLE 5 SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009 (%)	26
TABLE 6 ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE, 2008-2010	30
TABLE 7 CANCER PAIN MEDICATION	33
TABLE 8 ESTIMATED HIV REPORTED CASES BY REGION, 2011	36
TABLE 9 BURN CLASSIFICATIONS	37
TABLE 10 BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES	42
TABLE 11 U.S. SURGICAL PROCEDURES	44
TABLE 12 SELECT SURGICAL PROCEDURES FOR GERMANY, UNITED KINGDOM, AND FRANCE	45
TABLE 13 PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION* (THOUSANDS)	46
TABLE 14 AVAILABILITY OF EDUCATION IN PAIN MANAGEMENT BY SELECT REGION/COUNTRY	55
TABLE 15 TOTAL NUMBER OF ABUSE TREATMENT FACILITIES AND CLIENTS, 2000-2010	56
TABLE 16 BENEFITS OF PRESCRIPTION MONITORING PROGRAMS FOR MEDICAL BOARDS	58
TABLE 17 STATES WITH ELECTRONIC PRESCRIPTION MONITORING PROGRAMS	58
TABLE 18 STATE CONTROLLED SUBSTANCES SCHEDULING AUTHORITIES AND OTHER CONTACT INFORMATION	60
TABLE 19 NURSE CONTINUING EDUCATION REQUIREMENTS FOR PAIN MANAGEMENT, BY REQUIRING STATE	73
TABLE 20 PHYSICIANS PER 1,000 POPULATION BY YEAR AND COUNTRY (THOUSANDS)	74
TABLE 21 NUMBER OF PHYSICIAN PER 100,000 RESIDENT POPULATION, UNITED STATES, 2009	76
TABLE 22 AVAILABILITY OF INJECTABLE MORPHINE BY COUNTRY	78
TABLE 23 AVAILABILITY OF ORAL MORPHINE IN HOSPICE-TYPE SETTINGS BY COUNTRY	79
TABLE 24 WORLD HEALTH ORGANIZATION RANKING OF HEALTHCARE SYSTEMS, TOP 50 (2000)	82
TABLE 25 HEALTH EXPENDITURES AS PERCENTAGE OF GDP BY COUNTRY, 1980 TO 2010	83
TABLE 26 HOSPITAL USAGE STATISTICS, AVERAGE 2000-2010 (DAYS)	84
TABLE 27 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, BRAND NAME PRODUCTS	86
TABLE 28 LIST OF EXTENDED-RELEASE AND LONG-ACTING OPIOID PRODUCTS REQUIRED TO HAVE AN OPIOID REMS, GENERIC NAME PRODUCTS	87
TABLE 29 LIST OF TRANSMUCOSAL IMMEDIATE-RELEASE FENTANYL PRODUCTS REQUIRED TO HAVE TIRF REMS ACCESS PROGRAM	88
TABLE 30 LIST OF MARKETED ACETAMINOPHEN-CONTAINING PRESCRIPTION PRODUCTS	89
TABLE 31 ADVANTAGES OF IONTOPHORETIC DRUG DELIVERY	92
TABLE 32 RECENT FDA APPLICATIONS/APPROVALS, JANUARY 2010-OCTOBER 2012	94
TABLE 33 MOST COMMONLY USED GENERAL ANESTHETIC AGENTS	104

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 34 ACETAMINOPHEN AND ACETAMINOPHEN COMBINATION PRODUCTS	106
TABLE 35 ASPIRIN AND ASPIRIN COMBINATION PRODUCTS	107
TABLE 36 IBUPROFEN AND IBUPROFEN COMBINATION PRODUCTS	108
TABLE 37 KETOPROFEN PRODUCTS	108
TABLE 38 OTC NONSTEROID ANTI-INFLAMMATORIES	109
TABLE 39 ANTI-MIGRAINE PRODUCTS	109
TABLE 40 TOPICAL ANESTHETIC PRODUCTS	110
TABLE 41 UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY, 2002-2012 (THOUSANDS OF PEOPLE)	125
TABLE 42 HOSPICE STATISTICS, PATIENTS BY CHARACTERISTICS, 2009 AND 2010 (% OF TOTAL)	129
TABLE 43 HOSPICE STATISTICS, PATIENTS BY PRIMARY DIAGNOSIS (% OF TOTAL)	130
TABLE 44 NHPCO COMMITTEES AND TASK FORCES	132
TABLE 45 ESTIMATED NUMBER OF REGISTERED HOSPITALS BY SELECTED COUNTRY, 2010 ESTIMATES	133
TABLE 46 TOTAL NUMBER OF REGISTERED U.S. HOSPITALS BY TYPE, 2010	134
TABLE 47 GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET AT MANUFACTURERS' SALES LEVELS, THROUGH 2017 (\$ MILLIONS)	139
TABLE 48 PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKET SHARE BY REVENUE, 2012 (\$ MILLIONS)	142
TABLE 49 PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BY REVENUE, 2012 (\$ MILLIONS/%)	143
TABLE 50 PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE, 2012 (\$ MILLIONS)	145
TABLE 51 GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, THROUGH 2017 (\$ MILLIONS)	148
TABLE 52 GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY DEVICES—MANUFACTURER MARKET SHARE, 2012 (\$ MILLIONS)	150
TABLE 53 GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012 (\$ MILLIONS)	151
TABLE 54 PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE, THROUGH 2017 (\$ MILLIONS)	153
TABLE 55 PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BY SEGMENT, 2012 (%/\$ MILLIONS)	154
TABLE 56 DISTRIBUTION OF GLOBAL PAIN MANAGEMENT REVENUES BY REGION, 2012 (%/\$ MILLIONS)	156
TABLE 57 SELECTED PAIN-MANAGEMENT DRUG PIPELINES	159
TABLE 58 U.S. PATENT EXPIRATION DATES FOR SELECT PAIN DRUGS	167
TABLE 59 FIRST TIME PRESCRIPTION GENERIC PAIN MANAGEMENT AND APPROVALS, JANUARY 2004-OCTOBER 2012	169

## LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET, 2012 AND 2017 (\$ MILLIONS)	7
FIGURE 1 PAIN-MANAGEMENT TECHNIQUES	15
FIGURE 2 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 (MILLIONS)	21
FIGURE 3 GLOBAL POPULATION BY SELECTED COUNTRY, 2010 AND PROJECTED 2015 (MILLIONS)	22
FIGURE 4 GLOBAL LIFE EXPECTANCY AT BIRTH BY SELECTED COUNTRY, 1980 AND 2010 (YEARS)	24
FIGURE 5 GLOBAL CANCER DEATHS BY TYPE, 2008 (THOUSANDS)	25
FIGURE 6 SEVERE HEADACHE OR MIGRAINE, LOW BACK PAIN, AND NECK PAIN AMONG ADULTS 18 YEARS OF AGE AND OVER*, 2005-2009 (%)	27
FIGURE 7 ESTIMATED* PREVALENCE/INCIDENCE OF CONDITIONS AFFECTING THE WORLDWIDE ORTHOPEDIC INDUSTRY, AVERAGE FIGURE 2008-2010	31
FIGURE 8 CAUSES OF CANCER PAIN	32
FIGURE 9 ADULT PREVALENCE RATE, 2011 (%)	36
FIGURE 10 BURN PAIN MANAGEMENT APPROACH	40
FIGURE 11 BIRTH RATES AND BIRTHS BY COUNTRY, 2010 ESTIMATES	42
FIGURE 12 PAIN BY SELECTED CATEGORY AND GENDER IN THE 18+ U.S. POPULATION* (THOUSANDS)	47
FIGURE 13 TOTAL NUMBER OF ABUSE TREATMENT FACILITIES, 2000-2010	56
FIGURE 14 TOTAL NUMBER OF ABUSE TREATMENT CLIENTS, 2000-2010	57
FIGURE 15 PHYSICIANS PER 1,000 POPULATION BY COUNTRY, 2010*	75
FIGURE 16 NUMBER OF PHYSICIANS PER 100,000 RESIDENT POPULATION, UNITED STATES 2009	76
FIGURE 17 HOSPITAL USAGE STATISTICS (DAYS)	84
FIGURE 18 UNITED STATES: ADULTS 18 YEARS AND OVER WHO USED COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) IN THE PAST 12 MONTHS BY TYPE AND THERAPY, 2002-2012 (THOUSANDS OF PEOPLE)	125
FIGURE 19 TOTAL HOSPICE PATIENTS SERVED BY YEAR, 2006-2010 (TOTAL PATIENTS SERVED, ESTIMATE)	128
FIGURE 20 TOTAL HOSPICE PATIENTS BY GENDER, 2009 AND 2010 (% OF TOTAL)	129
FIGURE 21 TOTAL HOSPICE PATIENTS BY AGE, 2009 AND 2010 (% OF TOTAL)	130
FIGURE 22 TOTAL HOSPICE PATIENTS BY PRIMARY DIAGNOSIS, 2009 AND 2010 (% OF TOTAL)	131
FIGURE 23 GLOBAL PRESCRIPTION PAIN MANAGEMENT PHARMACEUTICALS MARKET AT MANUFACTURERS' SALES LEVELS, 2008-2017 (\$ MILLIONS)	139
FIGURE 24 PRESCRIPTION NARCOTIC AND NON-NARCOTIC MANUFACTURER MARKET SHARE BY REVENUE, 2012 (\$ MILLIONS)	142
FIGURE 25 PRESCRIPTION ANTI-MIGRAINE DRUG MANUFACTURER MARKET SHARE BY REVENUE, 2012 (%)	144
FIGURE 26 PRESCRIPTION ANESTHETIC MANUFACTURER MARKET SHARE BY REVENUE, 2012 (%)	145
FIGURE 27 GLOBAL PAIN MANAGEMENT DEVICES MARKET BY PRODUCT TYPE, 2008-2017 (\$ MILLIONS)	148
FIGURE 28 GLOBAL NEUROMUSCULAR STIMULATOR/TENS—ELECTROTHERAPY DEVICES—MANUFACTURER MARKET SHARE, 2012 (%)	150
FIGURE 29 GLOBAL SPINAL CORD STIMULATOR MANUFACTURER MARKET SHARE, 2012 (%)	151
FIGURE 30 PAIN MANAGEMENT PHARMACEUTICALS AND DEVICES MARKET BY REVENUE, 2008-2017 (\$ MILLIONS)	153

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 31 PERCENT DISTRIBUTION OF THE GLOBAL PAIN MANAGEMENT MARKET BY SEGMENT, 2012 (%)	154
FIGURE 32 PERCENTAGE DISTRIBUTION OF GLOBAL PAIN MANAGEMENT SHARES BY REGION, 2012 (%)	156